EP4702015A1 - Inhibiteurs de cdk2 et leurs procédés d'utilisation - Google Patents

Inhibiteurs de cdk2 et leurs procédés d'utilisation

Info

Publication number
EP4702015A1
EP4702015A1 EP24796058.6A EP24796058A EP4702015A1 EP 4702015 A1 EP4702015 A1 EP 4702015A1 EP 24796058 A EP24796058 A EP 24796058A EP 4702015 A1 EP4702015 A1 EP 4702015A1
Authority
EP
European Patent Office
Prior art keywords
heterocyclyl
cycloalkyl
compound
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24796058.6A
Other languages
German (de)
English (en)
Inventor
Hongjian YANG
Yexing CAO
Chang Bai
Jialiang QIN
Jing Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Touchstone Translational Research Institute Co Ltd
Foshan Ionova Biotherapeutics Co Inc
Shenzhen Ionova Life Science Co Ltd
Original Assignee
Guangdong Touchstone Translational Research Institute Co Ltd
Foshan Ionova Biotherapeutics Co Inc
Shenzhen Ionova Life Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Touchstone Translational Research Institute Co Ltd, Foshan Ionova Biotherapeutics Co Inc, Shenzhen Ionova Life Science Co Ltd filed Critical Guangdong Touchstone Translational Research Institute Co Ltd
Publication of EP4702015A1 publication Critical patent/EP4702015A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule (I) en tant qu'inhibiteurs de CDK2, qui sont utiles pour traiter des maladies ou des affections médiées par CDK2, en particulier, des cancers et d'autres maladies provoquées par une prolifération cellulaire anormale. L'invention concerne également des procédés de préparation, des compositions pharmaceutiques et des procédés d'utilisation.
EP24796058.6A 2023-04-24 2024-04-23 Inhibiteurs de cdk2 et leurs procédés d'utilisation Pending EP4702015A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2023090329 2023-04-24
US202363501034P 2023-05-09 2023-05-09
CN2023127659 2023-10-30
US202363615863P 2023-12-29 2023-12-29
PCT/CN2024/089320 WO2024222678A1 (fr) 2023-04-24 2024-04-23 Inhibiteurs de cdk2 et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
EP4702015A1 true EP4702015A1 (fr) 2026-03-04

Family

ID=93255543

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24796058.6A Pending EP4702015A1 (fr) 2023-04-24 2024-04-23 Inhibiteurs de cdk2 et leurs procédés d'utilisation

Country Status (6)

Country Link
EP (1) EP4702015A1 (fr)
KR (1) KR20260039645A (fr)
CN (1) CN121443596A (fr)
AU (1) AU2024259993A1 (fr)
IL (1) IL324169A (fr)
WO (1) WO2024222678A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
PL3060562T3 (pl) * 2013-10-21 2022-01-10 Genosco Podstawione związki pirymidynowe i ich zastosowanie jako inhibitory syk
WO2018226739A1 (fr) * 2017-06-06 2018-12-13 Signalrx Pharmaceuticals, Inc. Thiénopyranones et furanopyranones à titre d'inhibiteurs de point de contrôle et de modulateurs de l'immunité antitumorale
US20210101881A1 (en) * 2018-02-12 2021-04-08 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Pyrimidine compound, preparation method thereof and medical use thereof

Also Published As

Publication number Publication date
WO2024222678A1 (fr) 2024-10-31
CN121443596A (zh) 2026-01-30
IL324169A (en) 2025-12-01
KR20260039645A (ko) 2026-03-20
AU2024259993A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
CN110724143B (zh) 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
AU2012204982B2 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
KR102662358B1 (ko) Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
TWI551595B (zh) 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions
JP2019522055A (ja) Ｆｇｆｒ阻害剤として使用される複素環式化合物
JP2013535491A (ja) フタラジノンケトン誘導体、その製造法および医薬用途
TW202024037A (zh) 用於治療特定白血病之化合物
KR20150126391A (ko) 신규 피리미딘 및 피리딘 화합물 및 이들의 용도
EP3380475A1 (fr) Dérivés d&#39;octahydropyrrolo [3, 4-c
AU2024245104A1 (en) Compound acting as wrn helicase inhibitor
CA3015166C (fr) Composes 6,7-dihydro-5 h-pyrazolo [5,1-b] [1,3]oxazine-2-carboxamide
WO2021099832A2 (fr) Composés antagonistes des récepteurs de l&#39;adénosine
WO2015066697A1 (fr) Morpholinopyrimidines fusionnées et procédés d&#39;utilisation de ces dernières
CA3231988A1 (fr) Compose macrocycle azaindazole et son utilisation
AU2024259993A1 (en) Cdk2 inhibitors and methods of using same
WO2011082271A2 (fr) Composés triazolo-pyrimidine substitués
TWI894448B (zh) Ctla-4小分子降解劑及其應用
JP6977038B2 (ja) Ｇｓｋ−３阻害剤
CN114075196B (zh) 一类芳香环并内酰胺类化合物、其制备方法和用途
CA3223874A1 (fr) Composes de pyrimidine destines a etre utilises en tant qu&#39;inhibiteurs de map4k1
WO2024067820A1 (fr) Composés tricycliques en tant qu&#39;inhibiteurs de cdk et leurs procédés d&#39;utilisation
TW202604908A (zh) 雜環化合物及其作為ｒｅｔ抑制劑的用途
WO2023033740A1 (fr) Composés utiles dans la modulation de la signalisation ahr
EP4698531A1 (fr) Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques
FR3025200A1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR